-The Times of India NEW DELHI: Traffic challans will very soon be paid online across the country and will not constitute a court case. The government has written to all states to make online payment of traffic challans mandatory and the ministry of road transport and highways is likely to issue a directive to take challan cases out of the domain of courts. After the intervention of the Prime Minister's Office, the...
More »SEARCH RESULT
Total Matching Records found : 5366
Dalits flee Haryana village after upper caste attacks -Deepender Deswal
-The Times of India KAITHAL: As politicians and administrators in many northern Indian states were preparing to celebrate Dalit icon B R Ambedkar's 122nd birth anniversary this weekend, more than 100 Dalits were fleeing a small Haryana village after being chased by upper caste goons, angry that a Dalit man had dared to marry one of their girls. Meena and Surya Kant of Pabnama village in Kaithal were in a relationship for...
More »Social Justice
KEY TRENDS • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8 • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...
More »SC’s Novartis judgement renews focus on accessible medicine
The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...
More »Why Novartis case will help innovation-Achal Prabhala and Sudhir Krishnaswamy
-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...
More »
